Histone deacetylase (HDAC) inhibitors are a class of drugs used in the cancer treatment. Here, we developed a library of 19 analogues of Vorinostat, an HDAC inhibitor used in lymphomas treatment. In Vorinostat, we replaced the hydrophobic phenyl group with various tricyclic ‘caps’ possessing a central, eight-membered, heterocyclic ring, and investigated the HDAC activity and cytotoxic effect on the cancer and normal cell lines. We found that 3 out of the 19 compounds, based on dibenzo[b,f]azocin-6(5H)-one, 11,12-dihydrodibenzo[b,f]azocin-6(5H)-one, and benzo[b]naphtho[2,3-f][1,5]diazocine-6,14(5H,13H)-dione scaffolds, showed better HDACs inhibition than the referenced Vorinostat. In leukemic cell line MV4-11 and in the lymphoma cell line Daudi, three compounds showed lower IC50 values than Vorinostat. These compounds had higher activity and selectivity against MV4-11 and Daudi cell lines than reference Vorinostat. We also observed a strong correlation between HDACs inhibition and the cytotoxic effect. Cell lines derived from solid tumours: A549 (lung carcinoma) and MCF-7 (breast adenocarcinoma) as well as reference BALB/3T3 (normal murine fibroblasts) were less susceptible to compounds tested. Developed derivatives show improved properties than Vorinostat, thus they could be considered as possible agents for leukemia and lymphoma treatment.
组织脱乙酰化酶(H
DAC)
抑制剂是一类用于癌症治疗的药物。在这里,我们开发了一个包含19个似Vorinostat的H
DAC抑制剂类似物的文库,Vorinostat是一种用于淋巴瘤治疗的H
DAC抑制剂。在Vorinostat中,我们用各种含有中心八元杂环环的各种
三环“帽子”替换了疏
水苯基,并研究了这些化合物对癌细胞和正常
细胞系的H
DAC活性和细胞毒性影响。我们发现,在这19个化合物中,基于二苯并[b,f]氮杂环-6(5H)-酮、11,12-二氢二苯并[b,f]氮杂环-6(5H)-酮和苯并[b]
萘并[2,3-f][1,5]二氮杂环-6,14(5H,13H)-二酮骨架的三种化合物显示出比参考的Vorinostat更好的H
DAC抑制作用。在白血病
细胞系MV4-11和淋巴瘤
细胞系Daudi中,这三种化合物显示出比Vorinostat更低的IC50值。这些化合物对MV4-11和Daudi
细胞系的活性和选择性比参考的Vorinostat更高。我们还观察到H
DAC抑制和细胞毒性效应之间存在很强的相关性。来自实体肿瘤的
细胞系:A549(肺癌)和MCF-7(乳腺腺癌)以及参考的BALB/3T3(正常小鼠成纤维细胞)对所测试的化合物不太敏感。开发的衍
生物比Vorinostat具有改进的性质,因此它们可能被视为白血病和淋巴瘤治疗的可能药物。